A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2013
12/10/2013	US8603534 Drug loaded polymeric nanoparticles and methods of making and using same
12/10/2013	US8603531 Nanometer-sized prodrugs of NSAIDs
12/10/2013	US8603525 Multilayer orally disintegrating tablet
12/10/2013	US8603523 Pharmaceutical composition and its use in a method for treatment of patients with upper respiratory mucosal congestion
12/10/2013	US8603522 Nutritional supplement to treat macular degeneration
12/10/2013	US8603520 Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
12/10/2013	US8603519 Topical delivery of L-arginine to cause beneficial effects
12/10/2013	US8603507 Silicone oil emulsion, method of producing same, and silicone oil composition
12/10/2013	US8603506 Methods of treating acne
12/10/2013	US8603502 Compositions comprising jasmonic acid derivatives and use of these derivatives
12/10/2013	US8603501 Cancer cell targeting using nanoparticles
12/10/2013	US8603500 Cancer cell targeting using nanoparticles
12/10/2013	US8603499 Cancer cell targeting using nanoparticles
12/10/2013	US8603497 Composition for local anesthesia
12/10/2013	US8603489 Therapeutic proteins from latex
12/10/2013	US8603485 Bystander immune suppression as a predictor for response to a vaccine
12/10/2013	US8603464 Alkaline phosphatase to reduce weight gain or induce weight loss
12/10/2013	US8603455 Removal promoters and inhibitor for apoptosis cells in vivo
12/10/2013	US8603454 Cyclodextrin-based polymers for therapeutics delivery
12/10/2013	US8603453 Antimicrobial polymeric biguanide and acidic co-polymer composition and method of use
12/10/2013	US8603452 Method of preventing biofouling using an anti-fouling bio-hydrogel composition
12/10/2013	US8603440 Compressed chewing gum tablet
12/10/2013	US8603076 Microfabricated nanopore device for sustained release of therapeutic agent
12/10/2013	US8602961 Apparatus and method of stimulating elevation of glutathione levels in a subject
12/10/2013	US8602215 Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
12/10/2013	CA2810655C Modulators of atp-binding cassette transporters
12/10/2013	CA2767664C Compounds and compositions for the treatment of parasitic diseases
12/10/2013	CA2754839C Pharmaceutical composition comprising levamlodipine and chlorthalidone
12/10/2013	CA2739611C Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
12/10/2013	CA2736615C Method for classifying and treating physiologic brain imbalances using quantitative eeg
12/10/2013	CA2712258C Use of isothiocyanate derivatives as anti-myeloma agents
12/10/2013	CA2710650C Oral care product and methods of use and manufacture thereof
12/10/2013	CA2700824C Heterocyclic compounds as crth2 receptor antagonists
12/10/2013	CA2699611C Desaturase genes and uses thereof
12/10/2013	CA2698579C Desaturase genes and uses thereof
12/10/2013	CA2688472C Biphenylcarboxamide derivatives as hedgehog pathway modulators
12/10/2013	CA2659564C Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands
12/10/2013	CA2656851C Substituted cinnamoyl anthranilate compounds exhibiting anti-fibrotic activity
12/10/2013	CA2656825C Method of treatment and agents useful for same
12/10/2013	CA2650206C Novel crystal of 5-aminolevulinic acid phosphate and process for producing the same
12/10/2013	CA2643622C New crystalline form vi of agometaline, the process for making it and pharmaceutical compositions containing it
12/10/2013	CA2636837C Combination of triazine derivatives and insulin secretion stimulators
12/10/2013	CA2633940C Preventive or therapeutic agent for cardiac dysfunction or myocardial injury caused by ischemia or ischemia reperfusion
12/10/2013	CA2623117C Novel crystal forms of irinotecan hydrochloride
12/10/2013	CA2611636C Methods and compositions containing natural folates for protecting against radiation damage
12/10/2013	CA2609336C Quadraphasic continuous graduated estrogen contraceptive
12/10/2013	CA2608957C Pyrrolidine derivative or salt thereof
12/10/2013	CA2607496C Production of glucosamine from plant species
12/10/2013	CA2605272C Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
12/10/2013	CA2600904C Trifluoromethylbenzamide derivatives and therapeutic uses thereof
12/10/2013	CA2599511C 2-(4-oxo-4h-quinazolin-3-yl) acetamides and their use as vasopressin v3 antagonists
12/10/2013	CA2597339C Use of silymarine and/or the constituents thereof as promoters of the pigmentation of the skin or hair
12/10/2013	CA2592007C Triazolophthalazines
12/10/2013	CA2589975C Releasable polymeric conjugates based on aliphatic biodegradable linkers
12/10/2013	CA2583779C Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to m0dulation of the dopamine d3 receptor
12/10/2013	CA2582911C Chemokine-binding heterocyclic compound salts, and methods of use thereof
12/10/2013	CA2580347C Halogenated benzamide derivatives
12/10/2013	CA2578958C Acetylated starch or starch succinate for treatment of obesity or diabetes
12/10/2013	CA2566092C Crystalline forms of duloxetine free base
12/10/2013	CA2565915C Inhalation powder formulations containing enantiomerically pure beta-agonists
12/10/2013	CA2557848C Ion binding compositions
12/10/2013	CA2556940C Modulator
12/10/2013	CA2555115C New crystalline form v of agomelatine, process for its preparation and pharmaceutical compositions containing it
12/10/2013	CA2552317C Hcv ns-3 serine protease inhibitors
12/10/2013	CA2544235C Dialysates and methods and systems related thereto
12/10/2013	CA2536015C Modified oligonucleotides for telomerase inhibition
12/10/2013	CA2532825C Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions
12/10/2013	CA2499220C Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
12/10/2013	CA2495442C Backbone-substituted bifunctional dota ligands, complexes and compositions thereof, and methods of using same
12/10/2013	CA2489250C Composition comprising viscous fibers and viscosity-lowering proteins
12/10/2013	CA2486385C Histone deacetylase inhibitors based on trihalomethylcarbonyl compounds
12/10/2013	CA2478612C Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
12/10/2013	CA2476984C Lactoferrin as an agent for enhancing action of an opioid
12/10/2013	CA2471947C Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex
12/10/2013	CA2465314C Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
12/10/2013	CA2465040C An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
12/10/2013	CA2453173C Mycobacterial antigens expressed during latency
12/10/2013	CA2451026C Mycobacterial antigens expressed under low oxygen tension
12/10/2013	CA2443617C Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions
12/10/2013	CA2415325C Preventing airway mucus production by administration of egf-r antagonists
12/10/2013	CA2385528C Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
12/10/2013	CA2385032C G protein-coupled receptor up-regulated in prostate cancer and uses thereof
12/06/2013	DE202012012818U1 Hautpflaster zur Absorbierung von Giftstofffen aus dem Körper A skin patch to absorb Giftstofffen from the body
12/05/2013	WO2013181495A2 Compositions comprising an anti-pdgf aptamer and a vegf antagonist
12/05/2013	WO2013181488A2 Inhibition of leukemic stem cells by pp2a activating agents
12/05/2013	WO2013181462A1 Use of amg 900 for the treatment of cancer
12/05/2013	WO2013181451A1 Treatment of multiple sclerosis and psoriasis using prodrugs of methyl hydrogen fumarate
12/05/2013	WO2013181391A2 7-disubstituted-phenyl tetracycline derivatives
12/05/2013	WO2013181348A1 Polysaccharide compositions and methods of use
12/05/2013	WO2013181332A1 Nitric oxide donor neprilysin inhibitors
12/05/2013	WO2013181296A2 Compositions and methods for managing weight
12/05/2013	WO2013181292A1 Nitisinone formulations
12/05/2013	WO2013181251A1 Crizotinib hydrochloride salt in crystalline
12/05/2013	WO2013181232A2 Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
12/05/2013	WO2013181217A2 Novel compounds and compositions for treatment of breathing control disorders or diseases
12/05/2013	WO2013181202A2 Chromane compounds
12/05/2013	WO2013181174A2 Solid dosage formulations of an orexin receptor antagonist
12/05/2013	WO2013181135A1 Quinazoline derivatives, compositions, and uses related thereto
12/05/2013	WO2013181084A1 Antispasmodic 1,2-diols and 1,2,3-triols
12/05/2013	WO2013180949A1 Substituted quinoline compounds and methods of use

1 ... 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 ... 7860